News
LEXX
4.430
+5.98%
0.250
Weekly Report: what happened at LEXX last week (1109-1113)?
Weekly Report · 2d ago
Weekly Report: what happened at LEXX last week (1102-1106)?
Weekly Report · 11/09 09:07
Lexaria Signs Third Pharmaceutical Agreement for DehydraTECH
TipRanks · 11/04 16:12
Lexaria Bioscience enters new pharmaceutical agreement for DehydraTECH
TipRanks · 11/04 14:15
Lexaria Bioscience Strikes Agreement With Undisclosed Pharma Firm To Investigate Lexaria's DehydraTECH Technology With One, More PharmCo Modules
Benzinga · 11/04 14:10
Weekly Report: what happened at LEXX last week (1026-1030)?
Weekly Report · 11/02 09:07
Lexaria Bioscience announces 70th patent award
TipRanks · 10/28 13:15
Lexaria Celebrates its 70th Patent Award
Barchart · 10/28 08:10
Weekly Report: what happened at LEXX last week (1019-1023)?
Weekly Report · 10/26 09:07
Lexaria Bioscience reaches full enrollment in GLP-1-H26-7 study
TipRanks · 10/21 13:35
Lexaria Bioscience Completes Enrollment And Continues Dosing On Schedule In Two Oral Semaglutide Pilot Study Comparing DehydraTECH Formulations To Wegovy Tablets
Benzinga · 10/21 13:29
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
Barchart · 10/21 08:25
Weekly Report: what happened at LEXX last week (1012-1016)?
Weekly Report · 10/19 09:07
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/16 21:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/15 21:05
Lexaria Marks Major Brain Uptake Gains in New DehydraTECH Study
TipRanks · 10/15 15:10
Lexaria Bioscience announces results from animal study GLP-1-A26-1
TipRanks · 10/15 13:21
Lexaria Bioscience Announces Results From Animal Study GLP-1-A26-1 Evaluating Both DehydraTECH-CBD Compositions And DehydraTECH-Semaglutide; Unfortunately, The DHT-SEMA Concentrations In Brain Tissue Were All At Levels Below The Lower Limit Of Quantitation Of The Bioassay Utilized In This Study
Benzinga · 10/15 13:15
Lexaria Announces Results from Animal Study GLP-1-A26-1
Barchart · 10/15 08:10
Weekly Report: what happened at LEXX last week (1005-1009)?
Weekly Report · 10/12 09:07
More
Webull provides a variety of real-time LEXX stock news. You can receive the latest news about Lexaria Bioscience Corp through multiple platforms. This information may help you make smarter investment decisions.
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.